Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease

Bibliography

• Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 2002;53:503-14
   PubMed Web of Science ®Google Scholar
• Ignarro LJ, Napoli C. Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis. Curr Atheroscler Rep 2004;6:281-7
   PubMedGoogle Scholar
• Wilkinson IB, Franklin SS, Cockcroft JR. Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology. Hypertension 2004;44:112-6
   PubMed Web of Science ®Google Scholar
• Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004;24:1023-30
   PubMed Web of Science ®Google Scholar
• Cooke JP. ADMA: its role in vascular disease. Vasc Med 2005;10(Suppl 1):S11-7
   PubMed Web of Science ®Google Scholar
• Kielstein JT, Donnerstag F, Gasper S, et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006;37:2024-9
   PubMed Web of Science ®Google Scholar
• Zhang GG, Bai YP, Chen MF, et al. Asymmetric dimethylarginine induces TNF-alpha production via ROS/NF-kappaB dependent pathway in human monocytic cells and the inhibitory effect of reinioside C. Vasc Pharmacol 2008;48:115-21
   PubMed Web of Science ®Google Scholar
• Ogawa T, Kimoto M, Sasaoka K. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 1989;264:10205-9
   PubMed Web of Science ®Google Scholar
• Leiper JM, Santa MJ, Chubb A, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999;343(Pt 1):209-14
   PubMed Web of Science ®Google Scholar
• Nijveldt RJ, Teerlink T, van Guldener C, et al. Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. Nephrol Dial Transplant 2003;18:2542-50
   PubMed Web of Science ®Google Scholar
• Nijveldt RJ, Teerlink T, Siroen MP, et al. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr 2003;22:17-22
   PubMed Web of Science ®Google Scholar
• Tran CT, Fox MF, Vallance P, Leiper JM. Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics 2000;68:101-5
   PubMed Web of Science ®Google Scholar
• Dayoub H, Achan V, Adimoolam S, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 2003;108:3042-7
   PubMed Web of Science ®Google Scholar
• Dayoub H, Rodionov R, Lynch C, et al. Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation. Stroke 2008;39:180-4
   PubMed Web of Science ®Google Scholar
• Teerlink T. ADMA metabolism and clearance. Vasc Med 2005;10(Suppl 1):S73-81
   PubMed Web of Science ®Google Scholar
• Murray-Rust J, Leiper J, McAlister M, et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol 2001;8:679-83
   PubMedGoogle Scholar
• Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 2002;99:13527-32
   PubMed Web of Science ®Google Scholar
• Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5
   PubMed Web of Science ®Google Scholar
• Ogawa T, Kimoto M, Sasaoka K. Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun 1987;148:671-7
   PubMed Web of Science ®Google Scholar
• Tain YL, Baylis C. Determination of dimethylarginine dimethylaminohydrolase activity in the kidney. Kidney Int 2007;72:886-9
   PubMed Web of Science ®Google Scholar
• Stone EM, Person MD, Costello NJ, Fast W. Characterization of a transient covalent adduct formed during dimethylarginine dimethylaminohydrolase catalysis. Biochemistry 2005;44:7069-78
   PubMed Web of Science ®Google Scholar
• Knipp M, Vasak M. A colorimetric 96-well microtiter plate assay for the determination of enzymatically formed citrulline. Anal Biochem 2000;286:257-64
   PubMed Web of Science ®Google Scholar
• Chobanyan K, Thum T, Suchy MT, et al. GC-MS assay for hepatic DDAH activity in diabetic and non-diabetic rats by measuring dimethylamine (DMA) formed from asymmetric dimethylarginine (ADMA): evaluation of the importance of S-nitrosothiols as inhibitors of DDAH activity in vitro and in vivo in humans. J Chromatogr B Analyt Technol Biomed Life Sci 2007;858:32-41
   PubMed Web of Science ®Google Scholar
• Jiang DJ, Hu GY, Jiang JL, et al. Relationship between protective effect of xanthone on endothelial cells and endogenous nitric oxide synthase inhibitors. Bioorg Med Chem 2003;11:5171-7
   PubMed Web of Science ®Google Scholar
• Maas R, Tan-Andreesen J, Schwedhelm E, et al. A stable-isotope based technique for the determination of dimethylarginine dimethylaminohydrolase (DDAH) activity in mouse tissue. J Chromatogr B Analyt Technol Biomed Life Sci 2007;851:220-8
   PubMed Web of Science ®Google Scholar
• Sasaki A, Doi S, Mizutani S, Azuma H. Roles of accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, and attenuated nitric oxide synthase activity in endothelial cells for pulmonary hypertension in rats. Am J Physiol Lung Cell Mol Physiol 2007;292:L1480-7
   PubMed Web of Science ®Google Scholar
• Prescott LM, Jones ME. Modified methods for the determination of carbamyl aspartate. Anal Biochem 1969;32:408-19
   PubMed Web of Science ®Google Scholar
• Hong L, Fast W. Inhibition of human dimethylarginine dimethylaminohydrolase-1 by S-nitroso-L-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia. J Biol Chem 2007;282:34684-92
   PubMed Web of Science ®Google Scholar
• Chen BM, Xia LW, Zhao RQ. Determination of N(G),N(G)-dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997;692:467-71
   PubMed Web of Science ®Google Scholar
• Pettersson A, Uggla L, Backman V. Determination of dimethylated arginines in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997;692:257-62
   PubMedGoogle Scholar
• Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842-7
   PubMed Web of Science ®Google Scholar
• Siroen MP, Teerlink T, Bolte AC, et al. No compensatory upregulation of placental dimethylarginine dimethylaminohydrolase activity in preeclampsia. Gynecol Obstet Invest 2006;62:7-13
   PubMed Web of Science ®Google Scholar
• Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002;106:987-92
   PubMed Web of Science ®Google Scholar
• Ellger B, Richir MC, van Leeuwen PA, et al. Glycemic control modulates arginine and asymmetrical-dimethylarginine levels during critical illness by preserving dimethylarginine-dimethylaminohydrolase activity. Endocrinology 2008;149:3148-57
   PubMed Web of Science ®Google Scholar
• Wang L, Zhou Y, Peng J, et al. Role of endogenous nitric oxide synthase inhibitor in gastric mucosal injury. Can J Physiol Pharmacol 2008;86:97-104
   PubMed Web of Science ®Google Scholar
• Tan B, Jiang DJ, Huang H, et al. Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway. Vasc Pharmacol 2007;46:338-45
   PubMed Web of Science ®Google Scholar
• Bulau P, Zakrzewicz D, Kitowska K, et al. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. Am J Physiol Lung Cell Mol Physiol 2007;292:L18-24
   PubMed Web of Science ®Google Scholar
• Jiang DJ, Jia SJ, Yan J, et al. Involvement of DDAH/ADMA/NOS pathway in nicotine-induced endothelial dysfunction. Biochem Biophys Res Commun 2006;349:683-93
   PubMed Web of Science ®Google Scholar
• Tang WJ, Hu CP, Chen MF, et al. Epigallocatechin gallate preserves endothelial function by reducing the endogenous nitric oxide synthase inhibitor level. Can J Physiol Pharmacol 2006;84:163-71
   PubMed Web of Science ®Google Scholar
• Scalera F, Kielstein JT, Martens-Lobenhoffer J, et al. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol 2005;16:892-8
   PubMed Web of Science ®Google Scholar
• Deng S, Deng PY, Jiang JL, et al. Aspirin protected against endothelial damage induced by LDL: role of endogenous NO synthase inhibitors in rats. Acta Pharmacol Sin 2004;25:1633-9
   PubMed Web of Science ®Google Scholar
• Jiang DJ, Jiang JL, Zhu HQ, et al. Demethylbellidifolin preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. J Ethnopharmacol 2004;93:295-306
   PubMed Web of Science ®Google Scholar
• Zhang WZ, Kaye DM. Simultaneous determination of arginine and seven metabolites in plasma by reversed-phase liquid chromatography with a time-controlled ortho-phthaldialdehyde precolumn derivatization. Anal Biochem 2004;326:87-92
   PubMed Web of Science ®Google Scholar
• Ueda S, Kato S, Matsuoka H, et al. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res 2003;92:226-33
   PubMed Web of Science ®Google Scholar
• Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 2007;30:1834-9
   PubMed Web of Science ®Google Scholar
• Hermenegildo C, Medina P, Peiro M, et al. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients. J Clin Endocrinol Metab 2002;87:5636-40
   PubMed Web of Science ®Google Scholar
• Billecke SS, Kitzmiller LA, Northrup JJ, et al. Contribution of whole blood to the control of plasma asymmetrical dimethylarginine. Am J Physiol Heart Circ Physiol 2006;291:H1788-96
   PubMed Web of Science ®Google Scholar
• Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002;303:131-7
   PubMed Web of Science ®Google Scholar
• Eid HM, Lyberg T, Arnesen H, Seljeflot I. Insulin and adiponectin inhibit the TNFalpha-induced ADMA accumulation in human endothelial cells: the role of DDAH. Atherosclerosis 2007;194:e1-8
   PubMedGoogle Scholar
• Martens-Lobenhoffer J, Bode-Boger SM. Simultaneous detection of arginine, asymmetric dimethylarginine, symmetric dimethylarginine and citrulline in human plasma and urine applying liquid chromatography-mass spectrometry with very straightforward sample preparation. J Chromatogr B Analyt Technol Biomed Life Sci 2003;798:231-9
   PubMed Web of Science ®Google Scholar
• Martens-Lobenhoffer J, Bode-Boger SM. Fast and efficient determination of arginine, symmetric dimethylarginine, and asymmetric dimethylarginine in biological fluids by hydrophilic-interaction liquid chromatography-electrospray tandem mass spectrometry. Clin Chem 2006;52:488-93
   PubMed Web of Science ®Google Scholar
• Schwedhelm E. Quantification of ADMA: analytical approaches. Vasc Med 2005;10(Suppl 1):S89-95
   PubMed Web of Science ®Google Scholar
• Loyaga-Rendon RY, Sakamoto S, Beppu M, et al. Accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, attenuated dimethylarginine dimethylaminohydrolase activity and intimal hyperplasia in premenopausal human uterine arteries. Atherosclerosis 2005;178:231-9
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Isotani E, Ohno K, et al. Involvement of accumulated NOS inhibitors and endothelin-1, enhanced arginase, and impaired DDAH activities in pulmonary dysfunction following subarachnoid hemorrhage in the rabbit. Vasc Pharmacol 2008;48:21-31
   PubMed Web of Science ®Google Scholar
• Imamura M, Waseda Y, Marinova GV, et al. Alterations of NOS, arginase, and DDAH protein expression in rabbit cavernous tissue after administration of cigarette smoke extract. Am J Physiol Regul Integr Comp Physiol 2007;293:R2081-9
   PubMed Web of Science ®Google Scholar
• Schulze F, Wesemann R, Schwedhelm E, et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004;42:1377-83
   PubMed Web of Science ®Google Scholar
• Konukoglu D, Firtina S, Serin O. The relationship between plasma asymmetrical dimethyl-L-arginine and inflammation and adhesion molecule levels in subjects with normal, impaired, and diabetic glucose tolerance. Metabolism 2008;57:110-5
   PubMed Web of Science ®Google Scholar
• Blackwell S, O'Reilly DS, Talwar D. Biological variation of asymmetric dimethylarginine and related arginine metabolites and analytical performance goals for their measurement in human plasma. Eur J Clin Invest 2007;37:364-71
   PubMed Web of Science ®Google Scholar
• Valtonen P, Karppi J, Nyyssonen K, et al. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2005;828:97-102
   PubMed Web of Science ®Google Scholar
• Knipp M, Charnock JM, Garner CD, Vasak M. Structural and functional characterization of the Zn(II) site in dimethylargininase-1 (DDAH-1) from bovine brain. Zn(II) release activates DDAH-1. J Biol Chem 2001;276:40449-56
   PubMed Web of Science ®Google Scholar
• Frey D, Braun O, Briand C, et al. Structure of the mammalian NOS regulator dimethylarginine dimethylaminohydrolase: a basis for the design of specific inhibitors. Structure 2006;14:901-11
   PubMed Web of Science ®Google Scholar
• Knipp M, Braun O, Gehrig PM, et al. Zn(II)-free dimethylargininase-1 (DDAH-1) is inhibited upon specific Cys-S-nitrosylation. J Biol Chem 2003;278:3410-6
   PubMed Web of Science ®Google Scholar
• Braun O, Knipp M, Chesnov S, Vasak M. Specific reactions of S-nitrosothiols with cysteine hydrolases: a comparative study between dimethylargininase-1 and CTP synthetase. Protein Sci 2007;16:1522-34
   PubMed Web of Science ®Google Scholar
• Maret W. Zinc coordination environments in proteins as redox sensors and signal transducers. Antioxid Redox Signal 2006;8:1419-41
   PubMed Web of Science ®Google Scholar
• Kang ES, Cates TB, Harper DN, et al. An enzyme hydrolyzing methylated inhibitors of nitric oxide synthase is present in circulating human red blood cells. Free Radic Res 2001;35:693-707
   PubMed Web of Science ®Google Scholar
• Simons TJ. Intracellular free zinc and zinc buffering in human red blood cells. J Membr Biol 1991;123:63-71
   PubMed Web of Science ®Google Scholar
• Achan V, Tran CT, Arrigoni F, et al. all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res 2002;90:764-9
   PubMed Web of Science ®Google Scholar
• Garbin U, Pasini AF, Stranieri C, et al. Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity. Pharmacol Res 2007;56:515-21
   PubMed Web of Science ®Google Scholar
• Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999;43:542-8
   PubMed Web of Science ®Google Scholar
• Jones LC, Tran CT, Leiper JM, et al. Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun 2003;310:836-43
   PubMed Web of Science ®Google Scholar
• Wakino S, Hayashi K, Tatematsu S, et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res 2005;28:255-62
   PubMed Web of Science ®Google Scholar
• Scalera F, Martens-Lobenhoffer J, Bukowska A, et al. Effect of telmisartan on nitric oxide–asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging. Hypertension 2008;51:696-703
   PubMed Web of Science ®Google Scholar
• Monsalve E, Oviedo PJ, Garcia-Perez MA, et al. Estradiol counteracts oxidized LDL-induced asymmetric dimethylarginine production by cultured human endothelial cells. Cardiovasc Res 2007;73:66-72
   PubMed Web of Science ®Google Scholar
• Charitidou C, Farmakiotis D, Zournatzi V, et al. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis 2008;196:958-65
   PubMed Web of Science ®Google Scholar
• Post MS, Verhoeven MO, van der Mooren MJ, et al. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women. J Clin Endocrinol Metab 2003;88:4221-6
   PubMed Web of Science ®Google Scholar
• Teerlink T, Neele SJ, de Jong S, et al. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin Sci (Lond) 2003;105:67-71
   PubMed Web of Science ®Google Scholar
• Verhoeven MO, Hemelaar M, van der Mooren MJ, et al. Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study. J Intern Med 2006;259:199-208
   PubMed Web of Science ®Google Scholar
• Holden DP, Cartwright JE, Nussey SS, Whitley GS. Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. Circulation 2003;108:1575-80
   PubMed Web of Science ®Google Scholar
• Pan J, Baker KM. Retinoic acid and the heart. Vitam Horm 2007;75:257-83
   PubMed Web of Science ®Google Scholar
• Choudhary R, Palm-Leis A, Scott RC III, et al. All-trans retinoic acid prevents development of cardiac remodeling in aortic banded rats by inhibiting the renin-angiotensin system. Am J Physiol Heart Circ Physiol 2008;294:H633-44
   PubMed Web of Science ®Google Scholar
• Wang HJ, Zhu YC, Yao T. Effects of all-trans retinoic acid on angiotensin II-induced myocyte hypertrophy. J Appl Physiol 2002;92:2162-8
   PubMed Web of Science ®Google Scholar
• Bjelakovic G, Nikolova D, Gluud LL, et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2008;CD007176
   Google Scholar
• Munteanu A, Zingg JM. Cellular, molecular and clinical aspects of vitamin E on atherosclerosis prevention. Mol Aspects Med 2007;28:538-90
   PubMed Web of Science ®Google Scholar
• Onozato ML, Tojo A, Leiper J, et al. Expression of NG,NG-dimethylarginine dimethylaminohydrolase and protein arginine N-methyltransferase isoforms in diabetic rat kidney: effects of angiotensin II receptor blockers. Diabetes 2008;57:172-80
   PubMed Web of Science ®Google Scholar
• Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo italiano per lo studio della sopravvivenza nell'infarto miocardico. Lancet 1999;354:447-55
   PubMed Web of Science ®Google Scholar
• Wang Y, Shi JG, Wang MZ, et al. Mechanisms of the vasorelaxant effect of 1, 5-dihydroxy-2, 3-dimethoxy-xanthone, an active metabolite of 1-hydroxy-2, 3, 5-trimethoxy-xanthone isolated from a Tibetan herb, Halenia elliptica, on rat coronary artery. Life Sci 2008;82:91-8
   PubMed Web of Science ®Google Scholar
• Dai Z, Jiang DJ, Hu GY, et al. 3,4,5,6-Tetrahydroxyxanthone protects against myocardial ischemia-reperfusion injury in rats. Cardiovasc Drugs Ther 2004;18:279-88
   PubMed Web of Science ®Google Scholar
• Madan B, Prasad AK, Parmar VS, Ghosh B. 1,4-dihydroxyxanthone modulates the adhesive property of endothelial cells by inhibiting intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin. Bioorg Med Chem 2004;12:1431-7
   PubMed Web of Science ®Google Scholar
• Rosendorff C. Effects of LDL cholesterol on vascular function. J Hum Hypertens 2002;16(Suppl 1):S26-8
   PubMedGoogle Scholar
• Babu PV, Liu D. Green tea catechins and cardiovascular health: an update. Curr Med Chem 2008;15:1840-50
   PubMed Web of Science ®Google Scholar
• Widlansky ME, Hamburg NM, Anter E, et al. Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary artery disease. J Am Coll Nutr 2007;26:95-102
   PubMed Web of Science ®Google Scholar
• Nagao T, Hase T, Tokimitsu I. A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. Obesity (Silver Spring) 2007;15:1473-83
   PubMed Web of Science ®Google Scholar
• Militante JD, Lombardini JB. Treatment of hypertension with oral taurine: experimental and clinical studies. Amino Acids 2002;23:381-93
   PubMed Web of Science ®Google Scholar
• Steinberg HO, Baron AD. Insulin-dependent diabetes mellitus and nitrovasodilation. Important and complex interactions. Circulation 1997;95:560-1
   PubMed Web of Science ®Google Scholar
• Beltowski J, Jamroz-Wisniewska A, Widomska S. Adiponectin and its role in cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets 2008;8:7-46
   PubMedGoogle Scholar
• Despres JP, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008;28:1039-49
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman E, Bolton WK. Pimagedine: a novel therapy for diabetic nephropathy. Expert Opin Investig Drugs 2002;11:565-74
   PubMed Web of Science ®Google Scholar
• Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001;357:593-615
   PubMed Web of Science ®Google Scholar
• Su J, Lucchesi PA, Gonzalez-Villalobos RA, et al. Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice. Arterioscler Thromb Vasc Biol 2008;28:1432-8
   PubMed Web of Science ®Google Scholar
• Yin QF, Fu SH, He P, Xiong Y. Dimethylarginine dimethylaminohydrolase inhibition and asymmetric dimethylarginine accumulation contribute to endothelial dysfunction in rats exposed to glycosylated protein: effects of aminoguanidine. Atherosclerosis 2007;190:53-61
   PubMed Web of Science ®Google Scholar
• Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004;24:32-40
   PubMed Web of Science ®Google Scholar
• Arnal JF, Douin-Echinard V, Brouchet L, et al. Understanding the oestrogen action in experimental and clinical atherosclerosis. Fundam Clin Pharmacol 2006;20:539-48
   PubMed Web of Science ®Google Scholar
• Qiao X, McConnell KR, Khalil RA. Sex steroids and vascular responses in hypertension and aging. Gend Med 2008;5(Suppl A):S46-64
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-33
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and estrogen/progestin replacement study (HERS) research group. JAMA 1998;280:605-13
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002;53:605-19
   PubMed Web of Science ®Google Scholar
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
   PubMed Web of Science ®Google Scholar
• Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005;46:1425-33
   PubMed Web of Science ®Google Scholar
• Chen YH, Lin SJ, Chen YL, et al. Anti-inflammatory effects of different drugs/agents with antioxidant property on endothelial expression of adhesion molecules. Cardiovasc Hematol Disord Drug Targets 2006;6:279-304
   PubMedGoogle Scholar
• Tsimihodimos V, Miltiadous G, Daskalopoulou SS, et al. Fenofibrate: metabolic and pleiotropic effects. Curr Vasc Pharmacol 2005;3:87-98
   PubMedGoogle Scholar
• Yin QF, Xiong Y. Pravastatin restores DDAH activity and endothelium-dependent relaxation of rat aorta after exposure to glycated protein. J Cardiovasc Pharmacol 2005;45:525-32
   PubMed Web of Science ®Google Scholar
• Yang TL, Chen MF, Luo BL, et al. Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity. Naunyn Schmiedebergs Arch Pharmacol 2005;371:401-7
   PubMed Web of Science ®Google Scholar
• Jiang JL, Zhang XH, Li NS, et al. Probucol decreases asymmetrical dimethylarginine level by alternation of protein arginine methyltransferase I and dimethylarginine dimethylaminohydrolase activity. Cardiovasc Drugs Ther 2006;20:281-94
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
   PubMed Web of Science ®Google Scholar
• Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004;110:1557-63
   PubMed Web of Science ®Google Scholar
• Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of scotland coronary prevention study. N Engl J Med 2007;357:1477-86
   PubMed Web of Science ®Google Scholar
• Scott R, O'brien R, Fulcher G, et al. The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study. Diabetes Care 2009;32:493-8
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
   PubMed Web of Science ®Google Scholar
• Tanaka N, Katayama Y, Katsumata T, et al. Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats. Brain Res 2007;1169:125-32
   PubMed Web of Science ®Google Scholar
• Young JM, Strey CH, George PM, et al. Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure. Eur J Heart Fail 2008;10:463-6
   PubMed Web of Science ®Google Scholar
• Santilli F, Bucciarelli L, Noto D, et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 2007;43:1255-62
   PubMed Web of Science ®Google Scholar
• Shinohara K, Shoji T, Kimoto E, et al. Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2005;12:205-10
   PubMed Web of Science ®Google Scholar
• Valkonen VP, Laakso J, Paiva H, et al. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? Atheroscler Suppl 2003;4:19-22
   PubMedGoogle Scholar
• Paiva H, Laakso J, Lehtimaki T, et al. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol 2003;41:219-22
   PubMed Web of Science ®Google Scholar
• Panichi V, Mantuano E, Paoletti S, et al. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. J Nephrol 2008;21:38-44
   PubMed Web of Science ®Google Scholar
• Boger GI, Rudolph TK, Maas R, et al. Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilation by simvastatin: effect of combination with oral L-arginine. J Am Coll Cardiol 2007;49:2274-82
   PubMed Web of Science ®Google Scholar
• Pereira EC, Bertolami MC, Faludi AA, et al. Effects of simvastatin and L-arginine on vasodilation, nitric oxide metabolites and endogenous NOS inhibitors in hypercholesterolemic subjects. Free Radic Res 2003;37:529-36
   PubMed Web of Science ®Google Scholar
• Janatuinen T, Laakso J, Laaksonen R, et al. Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults. Vasc Med 2003;8:185-9
   PubMed Web of Science ®Google Scholar
• Oguz A, Uzunlulu M. Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. Int Heart J 2008;49:303-11
   PubMed Web of Science ®Google Scholar
• Pat B, Yang T, Kong C, et al. Activation of ERK in renal fibrosis after unilateral ureteral obstruction: modulation by antioxidants. Kidney Int 2005;67:931-43
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Matsuno S, Kagota S, et al. Fluvastatin reduces modification of low-density lipoprotein in hyperlipidemic rabbit loaded with oxidative stress. Eur J Pharmacol 2002;436:97-105
   PubMed Web of Science ®Google Scholar
• Nagase S, Hirayama A, Ueda A, et al. Does fluvastatin really have an antioxidant effect in humans? Kidney Int 2005;68:1373-4
   PubMedGoogle Scholar
• Gupta S, Wright HM. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Ther 2008;26:189-202
   PubMed Web of Science ®Google Scholar
• Pasini AF, Garbin U, Stranieri C, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens 2008;21:1251-7
   PubMed Web of Science ®Google Scholar
• Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Chrysant GS. The pleiotropic effects of angiotensin receptor blockers. J Clin Hypertens 2006;8:261-8
   PubMed Web of Science ®Google Scholar
• Chen MF, Xie XM, Yang TL, et al. Role of asymmetric dimethylarginine in inflammatory reactions by angiotensin II. J Vasc Res 2007;44:391-402
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002;288:1491-8
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   PubMed Web of Science ®Google Scholar
• Ishibashi M, Egashira K, Hiasa K, et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002;40:687-93
   PubMed Web of Science ®Google Scholar
• Majithiya JB, Paramar AN, Balaraman R. Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc Res 2005;66:150-61
   PubMed Web of Science ®Google Scholar
• Buchanan TA, Meehan WP, Jeng YY, et al. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 1995;96:354-60
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-73
   PubMed Web of Science ®Google Scholar
• Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-81
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
   PubMed Web of Science ®Google Scholar
• Lipscombe LL, Gomes T, Levesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007;298:2634-43
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95
   PubMed Web of Science ®Google Scholar
• Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000;28:149-67
   PubMed Web of Science ®Google Scholar
• Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 2007;293:H3227-45
   PubMed Web of Science ®Google Scholar
• Dayal S, Rodionov RN, Arning E, et al. Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia. Am J Physiol Heart Circ Physiol 2008;295:H816-25
   PubMed Web of Science ®Google Scholar
• Boyde TR, Rahmatullah M. Optimization of conditions for the colorimetric determination of citrulline, using diacetyl monoxime. Anal Biochem 1980;107:424-31
   PubMed Web of Science ®Google Scholar
• Nonaka S, Tsunoda M, Aoyama C, Funatsu T. Determination of NG, NG-dimethyl-L-arginine in rat plasma and dimethylarginine dimethylaminohydrolase activity in rat kidney using a monolithic silica column. J Chromatogr B Analyt Technol Biomed Life Sci 2006;843:170-4
   PubMed Web of Science ®Google Scholar
• MacAllister RJ, Rambausek MH, Vallance P, et al. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 1996;11:2449-52
   PubMed Web of Science ®Google Scholar
• MacAllister RJ, Fickling SA, Whitley GS, Vallance P. Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol 1994;112:43-8
   PubMed Web of Science ®Google Scholar
• Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99:3092-5
   PubMed Web of Science ®Google Scholar
• Bogumil R, Knipp M, Fundel SM, Vasak M. Characterization of dimethylargininase from bovine brain: evidence for a zinc binding site. Biochemistry 1998;37:4791-8
   PubMed Web of Science ®Google Scholar
• Stuhlinger MC, Tsao PS, Her JH, et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001;104:2569-75
   PubMed Web of Science ®Google Scholar
• Jia SJ, Jiang DJ, Hu CP, et al. Lysophosphatidylcholine-induced elevation of asymmetric dimethylarginine level by the NADPH oxidase pathway in endothelial cells. Vasc Pharmacol 2006;44:143-8
   PubMed Web of Science ®Google Scholar
• Rossiter S, Smith CL, Malaki M, et al. Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase. J Med Chem 2005;48:4670-8
   PubMed Web of Science ®Google Scholar
• Xin HY, Jiang DJ, Jia SJ, et al. Regulation by DDAH/ADMA pathway of lipopolysaccharide-induced tissue factor expression in endothelial cells. Thromb Haemost 2007;97:830-8
   PubMed Web of Science ®Google Scholar
• Leiper J, Nandi M, Torondel B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007;13:198-203
   PubMed Web of Science ®Google Scholar
• Forbes SP, Druhan LJ, Guzman JE, et al. Mechanism of 4-HNE mediated inhibition of hDDAH-1: implications in no regulation. Biochemistry 2008;47:1819-26
   PubMed Web of Science ®Google Scholar
• Zhang GG, Shi RZ, Jiang DJ, et al. Involvement of the endothelial DDAH/ADMA pathway in nitroglycerin tolerance: the role of ALDH-2. Life Sci 2008;82:699-707
   PubMed Web of Science ®Google Scholar